Health Affairs, 26, no. 3 (2007): 750-760
doi: 10.1377/hlthaff.26.3.750
© 2007 by Project HOPE
 
New Online
 * Getting Health Reform Done
 * After the State of the Union
 * Incremental Reform
 * E-Health in Developing World
 * Most-Read Articles in 2009
This Article
* Figures Only
* Full Text (HTML)
* Reprint (PDF)
* Submit a response to this article
* Comments: View responses
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in Web of Science
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Web of Science (3)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Polinski, J. M.
* Articles by Fischer, M. A.
* Search for Related Content
PubMed
* Articles by Polinski, J. M.
* Articles by Fischer, M. A.
Related Collections
* Access To Care
* Managed Care - Medicaid
* Medicaid
* Mental Health/Substance Abuse
* Pharmaceuticals
* Consumer Issues

Case Studies

Medicaid’s Prior Authorization Program And Access To Atypical Antipsychotic Medications

Jennifer M. Polinski, Philip S. Wang and Michael A. Fischer

State Medicaid programs use prior authorization (PA) to control drug spending by requiring that specific conditions be met before allowing reimbursement. The extent to which PA policies respond to new developments concerning medication safety is not known. In April 2005 the Food and Drug Administration (FDA) issued an advisory describing increased mortality among elderly people with dementia taking atypical antipsychotics. More than a year later, no state had changed its PA policy in response. We discuss the roles of Medicaid and other insurers in responding to emerging drug safety issues and their challenges in weighing drug risks and benefits.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
Health Aff (Millwood)Home page
S. Crystal, M. Olfson, C. Huang, H. Pincus, and T. Gerhard
Broadened Use Of Atypical Antipsychotics: Safety, Effectiveness, And Policy Challenges
Health Aff., September 1, 2009; 28(5): w770 - w781.
[Abstract] [Full Text] [PDF]


Home page
Psychiatr. Serv.Home page
J. C. West, J. E. Wilk, D. S. Rae, I. S. Muszynski, M. R. Stipec, C. L. Alter, K. E. Sanders, S. Crystal, and D. A. Regier
Medicaid Prescription Drug Policies and Medication Access and Continuity: Findings From Ten States
Psychiatr Serv, May 1, 2009; 60(5): 601 - 610.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
J. M. Donohue, H. A. Huskamp, and S. H. Zuvekas
Dual Eligibles With Mental Disorders And Medicare Part D: How Are They Faring?
Health Aff., May 1, 2009; 28(3): 746 - 759.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
P. S. Wang, C. M. Ulbricht, and M. Schoenbaum
Improving Mental Health Treatments Through Comparative Effectiveness Research
Health Aff., May 1, 2009; 28(3): 783 - 791.
[Abstract] [Full Text] [PDF]


Home page
Psychiatr. Serv.Home page
Y. Zhang, A. S. Adams, D. Ross-Degnan, F. Zhang, and S. B. Soumerai
Effects of Prior Authorization on Medication Discontinuation Among Medicaid Beneficiaries With Bipolar Disorder
Psychiatr Serv, April 1, 2009; 60(4): 520 - 527.
[Abstract] [Full Text] [PDF]


Home page
Psychiatr. Serv.Home page
J. J. Parks, A. Q. Radke, and R. Tandon
Impact of the CATIE Findings on State Mental Health Policy
Psychiatr Serv, May 1, 2008; 59(5): 534 - 536.
[Abstract] [Full Text] [PDF]


Home page
Psychiatr. Serv.Home page
M. R. Law, D. Ross-Degnan, and S. B. Soumerai
Effect of Prior Authorization of Second-Generation Antipsychotic Agents on Pharmacy Utilization and Reimbursements
Psychiatr Serv, May 1, 2008; 59(5): 540 - 546.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
S. B. Soumerai, F. Zhang, D. Ross-Degnan, D. E. Ball, R. F. LeCates, M. R. Law, T. E. Hughes, D. Chapman, and A. S. Adams
Use Of Atypical Antipsychotic Drugs For Schizophrenia In Maine Medicaid Following A Policy Change
Health Aff., May 1, 2008; 27(3): w185 - w195.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
G. M. Anderson, D. Juurlink, and A. S. Detsky
Newly Approved Does Not Always Mean New and Improved
JAMA, April 2, 2008; 299(13): 1598 - 1600.
[Full Text] [PDF]

Comments:

Read all Comments

Medicaid’s Lack of Response to New Drug Safety Issues
Robert A. Berringer, et al.
Health Affairs, 13 Jun 2007 [Full text]
Are Resources The Only Limiting Factor?
Susan L Parker
Health Affairs, 28 Nov 2007 [Full text]